AOD9604 5mg

Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

Foundational study showing AOD9604 significantly reduced body weight gain in obese mice by increasing fat oxidation — without causing hyperglycaemia, reducing insulin secretion, or activating the hGH receptor.

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

Demonstrated that AOD9604 reduces body weight and fat by upregulating beta-3 adrenergic receptor expression in adipose tissue, restoring lipolytic sensitivity in obese mice.

AOD-9604 Metabolic

Drug development review confirming AOD-9604 entered Phase IIa clinical trials for obesity treatment, documenting its advancement into human clinical testing.

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

Intra-articular AOD9604 enhanced cartilage regeneration in an osteoarthritis model. Combined with hyaluronic acid, it was significantly more effective than either treatment alone.

Current updates in the medical management of obesity

Comprehensive review of anti-obesity medications positioning AOD9604 among compounds that reduce adiposity at the molecular level.

Obesity drugs in clinical development

Categorized AOD-9604 as a human growth hormone fragment that increases adipose tissue breakdown, placing it in the active clinical development pipeline alongside rimonabant and exenatide.

Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors

Mayo Clinic review noting AOD9604 was in clinical trials as a drug that improves adipose tissue function and fatty acid metabolism, with potential to reduce cardiovascular risk.

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells

Novel application showing hGH fragment 176-191 can enhance anti-cancer drug delivery efficacy, demonstrating the fragment has tumor-targeting binding properties beyond its lipolytic effects.